Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children

Mizolastine is a second generation antihistamine agent approved in Europe for the treatment of allergic rhinitis and skin conditions for which Sanofi-Synthelabo is developing a pediatric solution. Our objective was to design the population pharmacokinetic (PK) study of mizolastine pediatric solution in children. A bioavailability study of this solution compared to the marketed tablet H as performed in 18 young volunteers. These PK data were analyzed by nonlinear regression wing a two-compartment open model with zero-order absorption. From the estimated parameters, we designed population PK studies in two groups of children: 6 to 12 years and 2 to 6 years respectively. To compare several population designs and to derive the optimal ones, we used the determinant of the Fisher information matrix of the population characteristics using a first-order expansion of the model. We have evaluated a reference population design with IO samples (from 0.25 to 36 hr after drug intake) per child in 6 children, which could nor be implemented in practice for ethical reasons, We then derived optimal population designs with 1, 2, 3, 4, or 5 samples per child and a total of 60 samples. Finally, the designs that were implemented in the population PK study were compromise population designs with 60 samples: one defined for 20 children 6 to 12 years old, and one with 24 children 2 to 6 years. In the older group, the population design involved 8 children with a catheter from which 6 samples at lime 0.25, 0.5, 0.75, 2, 3, and 6hr after drug intake are collected. and 12 children with only one sample at lime 8, IZ, 24, or 36 hr. In the younger group, the population design involved 15 children with a catheter who are divided in three groups with four samples at different times from 0.25 to 6 hr after drug intake, and IZ children with only one sample at lime 8, 12, 18, or 24 hr. The expected average increase of Variances of these designs compared to the reference design were 1.6 and 1.8 for the older and younger group, respectively, which was decided to be acceptable. Better population designs would have invoiced three groups of children with five samples per child but could not be implemented in practice. The data of the PK study in children 6 to 12 years were available and were analyzed using NONMEM. A total of 53 concentrations were obtained in 18 children. The same two-compartment model with zero-order absorption was used. The interindividual variability in children was small. The estimated population parameters in children 6 to 12 years, were 0.28 L/kg for V-c/F, 0. 10 L/hr per kg for CL/F, 0.53 hr(-1) for lambda (1), 0.076 hr(-1) for lambda (2). and 0.49 hr for T-abs. These values were close to the median values observed in young volunteers when standardized to 70 kg: notably, CL/F in L/hr per kg was similar, so that a dose of 0.15 mg/kg o.d. for mizolastine pediatric solution should give an equivalent area under the curve to a 10 mg o.d. tablet in adults.